Rapid Medical Evidence Brief — Demonstration Sample

A simulated rapid evidence brief showing a focused question, evidence base, synthesis decision, limitations and decision implications. Not client work.

DEMONSTRATION SAMPLE — NOT CLIENT WORK

This simulated decision brief demonstrates how Malheiros Medical & Bioengineering Research scopes a focused question, separates evidence from inference and keeps limitations visible. It is not a client deliverable, clinical guideline or published article.

Focused question

Do astrocytic or lipid-handling biomarkers consistently become abnormal before phosphorylated tau in genetically at-risk Alzheimer’s disease populations, supporting their use as validated upstream biomarkers?

Executive answer

No. Astrocytic biomarkers can become abnormal years before symptoms, but the reviewed evidence did not show consistent precedence over phosphorylated tau. In the strict timing evidence, p-tau was earlier more often than the astrocytic marker, and no strict lipid-handling study measured a paired p-tau trajectory. The evidence therefore does not validate an astrocytic or lipid marker as an upstream biomarker.

Scientific status

  • Source project: independently conducted systematic-review project
  • Protocol: registered on OSF, DOI 10.17605/OSF.IO/54GEF
  • Protocol version 4.1: archived on Zenodo, DOI 10.5281/zenodo.22111898
  • Data lock used for this demonstration: 28 August 2026
  • Status: not presented here as a published article or peer-reviewed guideline

Evidence base

  • 1,614 records identified and 1,433 records screened
  • 72 reports assessed in full text
  • 25 reports representing 19 strict studies
  • 19 additional independent studies retained as contextual evidence
  • Nine strict timing studies yielding 14 dependent target–tau timing rows
  • No timing row supplied the paired uncertainty required for a confidence interval

Key findings

Temporal ordering

Across the nine strict timing studies, the eligible target marker was earlier in one study, near-contemporaneous in two and p-tau was earlier in six. These are study-level direction counts, not a pooled effect estimate.

Registered p-tau217 and p-tau231 endpoints

Four studies reported the registered p-tau217 or p-tau231 endpoints. P-tau was earlier in three and near-contemporaneous in one; the eligible astrocytic marker was never earlier.

Lipid-handling evidence

No strict lipid-handling study supplied a paired p-tau trajectory, and no included study measured the complete astrocytic lipid-handling to amyloid to p-tau sequence in the same participants.

Quantitative synthesis decision

A meta-analysis was not performed. Thresholds, assays, matrices and trajectory procedures differed; several rows and cohorts were dependent; and paired change-point uncertainty was absent. Pooling would have manufactured precision rather than resolving uncertainty.

Decision implication

  • Do not describe GFAP, YKL-40 or a lipid signature as a validated upstream biomarker on the basis of early presymptomatic association alone
  • Do not infer causal precedence from a study-defined threshold crossing
  • For biomarker development, prospectively test whether an astrocyte-enriched lipid signature predicts p-tau217 or p-tau231 conversion beyond genotype, estimated years to onset, amyloid status and baseline p-tau
  • Use a prespecified validation target and report incremental predictive value, calibration and uncertainty

Limitations that change confidence

  • Screening, extraction and immediate source verification were performed by one reviewer
  • Embase, Scopus and Web of Science were not executed because licensed access and native exports were unavailable
  • Assays, matrices, thresholds and cohort definitions were heterogeneous
  • Participant overlap was incompletely resolvable
  • Eight strict studies were high risk of bias and eleven had some concerns
  • The evidence cannot quantify a reliable lead time for either marker class

Bottom line

Early relative to symptoms is not the same as upstream of p-tau. The evidence supports continued biomarker development, but it does not support marketing or clinical language that treats an astrocytic or lipid-handling marker as a validated causal predecessor.

Request a focused evidence brief

Send one focused question, the intended audience and the decision deadline. We will return a written scope, delivery date and fixed price within one business day.

sidario@malheirosresearch.com